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CC BY-NC-ND license (http://creativAbstract Ureteral metastasis from prostate cancer is rare. Here, we report a case of ureteral
metastasis from prostate cancer in a 65-year-old man who presented with lower urinary tract
symptoms. The initial prostate-specific antigen level was 372 ng/mL, and the Gleason score
was 9 (4 þ 5). Abdominal computed tomography revealed right hydronephroureter and bony
metastasis but no obvious lymphadenopathy. The patient underwent bilateral orchiectomy. Af-
ter 6 months, the metastasized lesion in the middle ureter was completely resolved, as deter-
mined through ureteroscopy. After hormone therapy, the prostate-specific antigen level
decreased to <0.5 ng/mL. Discrete ureteral metastasis should be considered in advanced pros-
tate cancer patients with obstructive uropathy.
Copyright ª 2016, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Prostate cancer is one of the most common malignancies
and the sixth leading cause of death in men worldwide.
Commonly affected sites include the bones, lymph nodes,
lungs, and liver. However, prostate cancer can also invade
the ureters either by local extension of the cancer or byreport no potential financi
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nodes.1,2 Ureteral obstruction caused by metastasis in pa-
tients without obvious periureteral or retroperitoneal
lymph node involvement has rarely been reported. Here,
we present an unusual case with advanced-stage prostate
adenocarcinoma and right hydronephroureter secondary to
the obstruction of the discrete ureteral metastasis.nfinancial conflicts of interest.
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Figure 2 (A) Abdominal computed tomography revealing the
Discrete ureteral metastasis from prostate cancer 2432. Case Report
A 65-year-old man presented to our hospital with lower
urinary tract symptoms lasting for 1 year. Digital rectal
examination revealed an enlarged prostate gland
(6 cm  5 cm) with an irregular surface and firm consis-
tency palpated over the bilateral lobes. The initial
prostate-specific antigen (PSA) level was 372 ng/mL, and
the serum creatinine level was 1.8 mg/dL (normal range:
0.7e1.4 mg/dL). Transrectal ultrasound-guided prostate
biopsy showed adenocarcinoma with a Gleason score of 9
(4 þ 5). The tumor cells showed enlarged nuclei, prominent
nucleoli, and a focal signet-ring cell-like feature (Figure 1).
Abdominal computed tomography (CT; Figure 2A) for
cancer staging demonstrated right hydronephroureter,
obstructed at the middle segment of the right ureter, and
multiple osteoblastic bony metastases in the thoracolumbar
spine. A technetium (99mTc) medronic acid whole-body
bone scan also revealed multiple bony metastases.
Considering that the patient had Stage IV prostate cancer
(cT3bN0M1), he underwent bilateral orchiectomy. Ure-
teroscopy was performed concurrently to evaluate the
cause of the right ureteral obstruction, revealing a stricture
in the middle third part of the right ureter (Figure 2B).
Ureteroscopic biopsy of the stricture site showed tumor cell
infiltration, which was positive for cytokeratin (CK) AE1/
AE3 and PSA and negative for CK7 and CK20. Both the tumor
morphology and immunoprofile supported the prostatic
origin of the discrete ureteral metastatic lesion (Figure 3).
Because of the failure of retrograde double-J stenting,
percutaneous nephrostomy and antegrade double-J stent-
ing were performed. Percutaneous nephrostomy was
removed a few days later after notable improvement of the
hydronephroureter.
Six months after orchiectomy, the PSA level was 0.5 ng/
mL. The metastatic lesion in the middle third part of the
right ureter was completely resolved, as determined
through ureteroscopy. The ureteral lumen was smooth
without any indentation or obstruction. Microscopically,Figure 1 Prostate tissue revealing adenocarcinoma exhibit-
ing fused glands with enlarged nuclei and prominent nucleoli
(hematoxylin and eosin staining, 400).
obstruction level of the right hydroureter near the sacroiliac
joint (middle ureter) with a thickened ureter wall. No obvious
pelvic lymphadenopathy was detected. (B) A stricture in the
middle third of the right ureter demonstrated under fluoros-
copy. The white arrowhead indicates the ureter stricture site.only some chronic inflammatory tissues and fibrosis were
identified in the biopsy specimens. No tumor was detected.
3. Discussion
Prostate cancer is one of the most frequently diagnosed
malignancies in men. Metastatic lesions are commonly
observed in the bones, lymph nodes, lungs, and liver. Since
Benejam et al3 described the first case in 1987, few cases of
discrete ureteral metastatic lesions of prostatic origin have
been reported in the past few decades.
Several theories concerning the mechanisms underlying
metastasis to the ureter have been proposed, including
direct invasion of the tumor, lymphatic or hematogenous
spread, or upon instrumentation.3e5 The clinical
Figure 3 (A) Periureteral soft tissue showing tumor cell
infiltration, which is compatible with prostatic origin based on
the morphology (hematoxylin and eosin staining, 400) and (B)
prostate-specific antigen staining (immunohistochemical
staining, 400).
244 C.-Y. Kuo et al.manifestation in our patient differs from that of patients
with common prostatic metastasis. Abdominal CT revealed
no definitive metastatic lymph node or direct tumor inva-
sion. Moreover, the patient had no history of ureteralinstrumentation. Presumably, this type of discrete
spreading may be attributable to the segmental pattern of
the lymphatic drainage system of the ureter, which has no
direct drainage network from the region of the prostate
gland.6
According to current consensus, the treatment for
metastatic prostate carcinoma is hormone therapy,
including medical or surgical castration. Chalasani et al7
reported a case of prostate carcinoma invading from the
ureter to the renal pelvis and observed an unsatisfactory
outcome after androgen deprivation therapy for the
metastatic lesion. Nevertheless, our patient showed a
favorable response to hormone therapy, because the
metastatic ureteral lesion was undetectable at 6 months
follow-up.
In conclusion, we report a rare presentation of ureteral
metastasis originating from prostate adenocarcinoma. The
risk of discrete ureteral metastasis from prostatic origin
should be considered when ureteral obstruction is noted in
patients with advanced prostate cancer.
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